Gracell Biotechnologies Inc. (GRCL): Price and Financial Metrics
GET POWR RATINGS... FREE!
GRCL Stock Price Chart Interactive Chart >
GRCL Price/Volume Stats
| Current price | $13.60 | 52-week high | $33.70 |
| Prev. close | $12.79 | 52-week low | $9.75 |
| Day low | $12.56 | Volume | 46,300 |
| Day high | $14.04 | Avg. volume | 122,297 |
| 50-day MA | $11.66 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 914.52M |
Gracell Biotechnologies Inc. (GRCL) Company Bio
Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.
Latest GRCL News From Around the Web
Below are the latest news stories about Gracell Biotechnologies Inc that investors may wish to consider to help them evaluate GRCL as an investment opportunity.
Gracell Biotechnologies to Participate in Upcoming Virtual Investor Conferences in SeptemberSUZHOU, China and PALO ALTO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences: Citi 16th Annual BioPharma Conference One-on-one and small group meetings: September 8 - 10, 2021 Panel - Exploring |
Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results and Provides Corporate UpdateSUZHOU, China and PALO ALTO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported its unaudited financial results for the second quarter of the year and recent business highlights. Gracell will host a conference call today, Tuesday, August 17, at 8:00 am Eastern Time. “W |
Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid TumorsGracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced an exclusive license agreement with FutureGen Biopharm ("FutureGen"), an innovative biopharmaceutical company, to develop engineered immune cell therapies targeting Claudin 18.2 ("CLDN18.2") in solid tumors. |
Gracell Biotechnologies to Report Second Quarter Financial Results on Tuesday, August 17, 2021SUZHOU, China and PALO ALTO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will release financial results for the second quarter ended June 30, 2021, prior to the open of the U.S. financial markets on Tuesday, August 17. Gracell’s management team will host a correspondin |
Gracell Biotechnologies to Participate in Fireside Chat at the BTIG Virtual Biotechnology ConferenceSUZHOU, China and PALO ALTO, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the BTIG Virtual Biotechnology Conference 2021 (details below). BTIG Virtual Biotechnology Conference 2021 One-on-one and small group meetings: August 9-10, 202 |
GRCL Price Returns
| 1-mo | 34.12% |
| 3-mo | 3.42% |
| 6-mo | -11.69% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...